Study of GC1008 in Patients With Idiopathic Pulmonary Fibrosis (IPF)

Inclusion criteria

• Willing and able to provide written informed consent prior to any study-related procedures.
• Patients should have an established diagnosis of IPF.
• Pulmonary Function Tests (PFTs): FVC ≥ 50% and DLCO ≥ 25% of normal predicted values.
• Able to walk at least 500 feet (150 meters) during the 6-minute Walk Test (6MWT). During the 6MWT the patient must not require greater than 51/min supplemental oxygen to maintain oxygen saturation > 80%

Exclusion criteria

• Women who are pregnant or lactating; or who plan to become pregnant within 9 months after the infusion.
• Women of childbearing potential or men who are considering fathering a child unless taking medically acceptable contraceptive precautions;
• History of clinically significant environmental exposure, including dust, molds, asbestos, pigeons or other birds that may result in interstitial lung disease, or ingestion of a drug known to cause pulmonary fibrosis such as bleomycin.
• History of clinically significant respiratory diseases other than IPF.
• History of clinically significant cardiac, hepatic, or renal disease.
• History of cancer, precancerous state (e.g. familial polyposis, BRCA1, BRCA2), other than non-melanomatous skin cancer, within 5 years prior to Screening.
• Use of any investigational drug administered as part of a clinical trial within 12 weeks before Screening.
• Other pathology that might interfere with the assessment of the safety or efficacy of the test article.
• Other clinically significant, uncontrolled medical condition that, in the Investigator's opinion, might interfere with the assessment or follow-up.